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N-Myristoyl transferase (NMT) activity was measured in rat liver and H9 cells using an in vitro assay based on acylation of synthetic peptides. 
Glucosamine was found to inhibit the NMT activity. Using a synthetic peptide mimicking the N-terminus of HIV p27nef a K, value of 2.4 PM 
and a V,,,,, of 240 pmol/mg per h was found. In the presence of glucosamine the V,, was lowered indicating that glucosamine acted as a non- 
competitive inhibitor. Glucosamine also inhibited incorporation of radiolabelled myristic acid into H9 cell proteins in vivo. In liver cells using a 
peptide from the N-terminus of p60 SRC only the V,,, was affected. 
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1. INTRODUCTION 
Glucosamine has been shown to inhibit or interfere 
with glycosylation of a number of viruses [ 11. The con- 
sequences of this may be dependent on the virus and 
host cell in question. Semliki forest virus release is in- 
hibited by glucosamine but this is not the case for New- 
castle disease virus [2]. It was assumed that the altered 
glycosylation affected different functions in the viruses 
tested depending on the functions of glycosylations in 
each case. However, as pointed out by Hayman et al. 
[3], it was very surprising that deletion mutants of avian 
RNA tumor virus that lack glycoproteins are able to 
form virus particles [4,5], whereas glucosamine inhibits 
glycosylation as well as release of the normal avian 
RNA tumor virus [6]. These results suggest hat glucos- 
amine inhibits release of avian RNA tumor virus by in- 
terfering with a process different from glycosylation 
(see also [3]). 
glucosamine on N-myristoyl transferase (NMT) activity 
in vitro. Both the in vitro assay as well as myristic acid 
incorporation into H9 cells in culture was affected by 
glucosamine. 
2. MATERIALS AND METHODS 
Studies on N-terminal acylation of viral proteins have 
suggested that acylation of viral proteins is necessary 
for processing of precursors and release of intact par- 
ticles [7-lo]. If glucosamine inhibited not only 
glycosylation but also acylation, it would be expected 
that virus production would be inhibited, even in such 
cases where glycoproteins were absent. Alternatively, 
acylation of host cell proteins may be important for 
virus release in certain cases. 
N-Myristoyl transferase (NMT) activity was assayed by the transfer 
of [?]myristic acid from myristoyl-coenzyme A (myr-CoA, Amer- 
sham, England; 54 mCi/mmol) to synthetic peptides based on the N- 
terminal octapeptide sequence of HIV p27nef and p6Osrc. The assay 
was carried out at pH 7.5 in a buffer containing 20 mM Tris-hydroxy- 
methylaminomethane (Tris), 10 mM MgClz, 2 mM dithiothreitol, 1% 
Triton X-100, 0.2 mM EGTA and 0.25 pCi myr-CoA. 10 pg of cell 
lysate and synthetic peptide was included in the assay, the synthetic 
peptide concentration being 10 pmol/l unless otherwise stated. The 
incubation volume was 200 ~1 and the incubation temperature was 
37°C. After 1 h of incubation the assay was stopped by adding 110 ,ul 
of 8% trichloroacetic acid in methanol followed by centrifugation 
(So00 x g,, 5 min) at 4°C. The radiolabelled peptides were isolated 
by reverse-phase HPLC on 5 C4 columns (Machery-Nagel, FRG). 
Their elution was identified by synthetic myristoylated peptides. The 
buffer system used was an isocratic elution by 32% acetonitrile (ACN) 
in 0.1% trifluoroacetic acid (TFA) followed by a gradient to 80% 
ACN in O.lYo TFA in 15 min to elute the remaining radiolabelled 
myr-CoA. The radiolabel was measured by scintillation counting. 
Using N-terminal octapeptides from HIV p27nefand 
pl7gag as well as p6Osrc, all known to be acylated pro- 
teins in vivo [l l-131, we have determined the effects of 
The procedure described above was changed slightly to measure 
myristoylation of the N-terminal fragment of HIV pl7gag. In this 
case the peptide corresponded to the first 11 amino acids of HIV p17 
and had a Tyr in position 12 to allow iodination. Using iodinated pep- 
tide and unlabelled myr-CoA, myristoylation could be measured by 
the large change in retention time caused by the acylation. In this case 
the acylated product was isolated on a Cl8 column (Machery-Nagel, 
FRG) using a linear gradient from 32% to 80% ACN in 0.1% TFA 
over 20 min. The peptide was iodinated using the iodogen procedure 
P41. 
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The enzyme preparations used were from rat liver or human H9 
lymphoma cells. The liver preparation was obtained from male 
Wistar rats (200 g) by homogenization of the minced liver in a 20 mM 
Tris, 250 mM sucrose, 0.5 mM EGTA buffer (pH 7.5) followed by 
centrifugation at 20000 x gav for 10 min at 4°C. The H9 cells were 
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lysed by nitrogen cavitation and homogenization followed by frac- 
tionation using the same procedure as the liver cells. The material was 
frozen in aliquots at - 20°C. 
Synthetic peptides were prepared on an LKB Biolynx peptide syn- 
thesizer according to the instruction manual (LKB Biochrome, 
England). Coupling time was 60 min and the peptides were synthesiz- 
ed with a carboxyl terminal group. The decoupling and deprotection 
was carried out in 95% TFA, 2.5% anisole and 2.5% ethanedithiol 
for 2 h. The peptides were precipitated 5 times in diethyl ether and 
desalted on a Sephadex G-10 column (Pharmacia, Sweden). The syn- 
thetic myristoyl-octapeptides u ed as standards, were prepared by us- 
ing symmetrical anhydrides of myristic acid in coupling to the syn- 
thetic peptides. The peptides were purified to homogeneity on an LKB 
TSKlZOT Cl8 column using linear gradients from 32% to 80% ACN 
in 0.1% TFA over 120 min. 
The effect of glucosamine on fatty acid and amino acid incorpora- 
tion was quantitated by drying a 100~1 sample of either a [‘HI- 
myristate or a [‘%]amino acid labelled cell suspension on a 5 x 5 cm 
Whatman 3 mm filter paper followed by precipitation with 10% tri- 
chloroacetic acid. The filter paper was extracted five times with chlo- 
roform/methanol (2: 1, v/v) and dried. Radioactivity on the filter was 
determined by scintillation counting. 
3. RESULTS 
Rat liver cells contained NMT activity able to cata- 
lyze the incorporation of radioactive myristic acid from 
myristoyl-CoA into synthetic octapeptides. In fig. 1 the 
distribution of radiolabel incorporated into N-terminal 
p27nef octapeptide is shown on a C4 reverse-phase 
HPLC gradient. The radiolabel coeluted with synthetic 
myristoylated N-terminal p27nefoctapeptide. A similar 
gradient was also used to determine radiolabel incor- 
poration into an N-terminal p6Osrc octapeptide. This 
peptide eluted 2 min earlier on the same gradient as in- 
dicated by a synthetic myristoylated standard. The in- 
corporation of label into both of these peptides was 
time and protein dependent and had a pH optimum of 
7.5. Acylation of these two peptides and pl7gag was us- 
ed to determine NMT activity in liver and H9 cells. 
In fig.2A is shown the NMT activity in rat liver mem- 
brane as a function of increasing concentration of sub- 
strate (p6Osrc octapeptide). The K,,, was found to be 
5.9 ,uM and the Vmax was 43 pmol/mg per h. Also 
shown in fig.2A is the effect of glucosamine (20 mM) 
500 t
Fig. 1. Distribution of radiolabel incorporated into N-terminal p27nef 
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Fig.2. (A) NMT activity in rat liver membranes as a function of 
substrate concentration. The NMT activity was assayed using N- 
terminal p6Osrc octapeptide as a substrate in the absence (0) or 
presence (A) of glucosamine (20 mM). Values are means f SD, 
n = 3. (B) Lineweaver-Burk plots of NMT activity in rat liver mem- 
branes. NMT activity was measured with (A) or without (0) the 
presence of glucosamine (20 mM) using N-terminal p6Osrc octapep- 
tide as a substrate. The K,,, value was 5.9 PM and I’,,,,, 43 pmol/mg 
per h in the absence of inhibitor. In the presence of glucosamine the 
V,,,,, was lowered to 21 pmol/mg per h whereas the K,,, is unchanged. 
on the NMT activity as a function of substrate concen- 
tration. It was found that glucosamine inhibited by 
reducing the Vmax. A Lineweaver-Burk plot of the 
results is shown in fig.2B. 
The effect of glucosamine was tested not only on rat 
liver cells but also on H9 cell NMT activity. In table 1 
is shown a comparison of the effect of glucosamine on 
both liver and H9 cells. Also included is the effect of 
glucose at the same concentrations. Only glucosamine 
affected the NMT activity. 
The concentration dependency of the effect of 
glucosamine on NMT activity in both liver and H9 cells 
was tested using N-terminal pl7gug octapeptide as sub- 
strate (fig.3). The effect was found to be half-maximal 
at 0.8 mM glucosamine in H9 cells and 1.2 mM in liver 
cells. 
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Table 1, 
Cell type H9 r Liver r 
Kn 01M) 2.4 0.98 5.9 1.0 
V,, (relative) 1.0 1.0 
Km + glucosamine (20 mM) 3.1 0.95 6.1 1.0 
V,,,, + glucosamine (20 mM) 0.8 0.5 
Vm’,, + glucose (20 mM) 1 1 
H9 cell or liver cell NMT activity was assayed in the presence or 
absence of glucosamine (mM) as a function of substrate concentra- 
tion (FM). The V,, and Km values were determined. Also included 
is the effect of glucose on NMT activity (V,,,,). r is the correlation 
coefficient 
OO 
0 25 5 
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Fig.3. NMT activity in rat liver and H9 membranes as a function of 
glucosamine concentration. The NMT activity was assayed using 
p6Osrc (0) or pl’lgag (A) peptide as substrate and rat liver or H9 
membranes as enzyme source. Values are means f SD, n = 3. 
The effect of glucosamine on acylation in tissue 
culture cells was illustrated using an assay of total fatty 
acid incorporation into cells. In fig.4 is shown the incor- 
poration of [3H]myristic acid into H9 cell proteins and 
its inhibition by glucosamine. The effect of glucos- 
amine was found to be half-maximal at concentrations 
between 0.5 and 1 mM. This effect was not due to in- 
hibition of protein synthesis (fig.4). Using a filtration 
assay for incorporation of radiolabel into total cell pro- 
tein the half-maximal inhibition by glucosamine was 
found to be 0.8 mM. 
4. DISCUSSION 
NMT activity was found in both human H9 lym- 
phoma cells and rat liver cells. Similar activity has been 
described previously in both liver, brain [15] and yeast 
[16]. The enzyme activity in the liver cell lysate used 
here had the same order of affinity for the N-terminal 
src octapeptide as was found in a previous study [15]. 
The enzyme activity in H9 cells was very similar to the 
activity found in the rat liver cells in terms of pH op- 
timum and affinity for different peptides. The affinity 
for these two peptides was very similar in both H9 and 
rat liver cells. 
Glucosamme cone (mhl) 
Fig.4. t3H]Myristic acid and [%]amino acid incorporation in the 
presence of various concentrations of glucosamine. [‘H]Myristic acid 
(0) and [?]amino acid (A). Values are means f SD, n = 3. 
Previous studies on the effect of glucosamine on 
virus assembly and glycosylation have shown that al- 
though glucosamine inhibits glycosylation, this may not 
explain why it also inhibits virus release [3]. Non- 
glycosylated avian RNA sarcoma viruses have been 
found that are released normally, although not 
glycosylated and not infectious since binding of the 
virus to target cells was dependent on glycosylation 
[4,5]. However, these viruses have been found to be re- 
leased in the presence of glucosamine [6]. This was part- 
ly due to inhibition of protein synthesis by glucosamine, 
but also due to inhibition of processing of the synthesiz- 
ed precursors for viral proteins [3]. These results point 
to an effect by glucosamine on a process necessary for 
virus assembly but different from glycosylation. It was 
also observed that the virus protein precursors were 
synthesized although they were not glycosylated [3]. 
Thus a process necessary for transport of the proteins to 
the cell surface may have been affected by glucosamine. 
The results presented here show that acylation is in- 
hibited by glucosamine both in rat liver cells and H9 
cells. We found that this was due to a direct effect on 
the NMT activity in these cells. Glucosamine not only 
inhibited acylation in an in vitro assay for NMT activity 
but also inhibited acylation in tissue cultures of H9 
cells. Acylation of precursor proteins has been shown to 
be necessary for normal processing in the case of 
Molony MLV gag precursor proteins [9]. Acylation was 
also found to be necessary for transport of the SIV gag 
precursor to the plasma membrane [lo]. We found an 
inhibition by glucosamine on acylation but not on 
amino acid incorporation in H9 cells at a concentration 
range (0.5-5 mM) that did not affect protein synthesis. 
The observed inhibition by glucosamine on acylating 
activity in H9 cells may thus explain why glucosamine 
was found to inhibit assembly of certain viruses, since 
inhibition of acylation would prevent transport of the 
actylated viral proteins to the cell surface. 
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